{"contentid": 487912, "importid": NaN, "name": "Russia\u00e2\u0080\u0099s Geropharm plots leading role in domestic insulin market", "introduction": "Russian drugmaker Geropharm plans to become one of the leading players in the domestic insulins market within the next several years, with the possible launch of a biosimilar of ultra-long-acting insulin, produced by the Danish diabetes care giant Novo Nordisk, as well as a further expansion of its portfolio.", "content": "<p>Russian drugmaker Geropharm plans to become one of the leading players in the domestic insulins market within the next several years, with the possible launch of a biosimilar of ultra-long-acting insulin, produced by the Danish diabetes care giant Novo Nordisk (NOV: N), as well as a further expansion of its portfolio.</p>\n<p>Despite the fact that in 2014 the Russian Federal Service for Intellectual Property (Rospatent) postponed the end of the protection of Novo Nordisk&rsquo;s insulin from 2024 to 2028 in the Russian market, Geropharm still has plans to launch its biosimilar of Tresiba (insulin degludec), reports The Pharma Letter&rsquo;s localcorrespondent.&nbsp;&nbsp;</p>\n<p>In May 2020, the Russian company demanded to recognize the actions of Rospatent as illegal and oblige it to cancel the prolongation of a patent for Novo Nordisk&rsquo;s insulin, however these claims were rejected by the Russian Intellectual Property Court on January 2021. At present this ultra-long-acting drug (more than 42 hours) is represented in the market by Tresiba and, in combination with ultra-short-acting insulin, Ryzodeg (insulin degludec + insulin aspart), being registered in 2013.&nbsp;</p>\n<p><strong>Could mean drugmakers won&rsquo;t be able to introduce biosimilars for several years</strong></p>\n<p>The latest decision of the court means that other manufacturers, including Geropharm will not be able to bring its biosimilars of insulin degludec to the market for at least the next several years. Geropharm, however, reported about its plans to challenge the legality of Rospatent's actions.</p>\n<p>According to the local analyst company DSM Group, for the 11 months of 2020 sales of Tresiba in the Russian market amounted to 653,000 units or 1.2 billion roubles (~$16 million).</p>\n<p>In the overall structure of insulin market in Russia, which is valued 29 billion roubles ($391 million), the share of long-acting insulins is equivalent to 14 billion roubles, where Tudgeo, Levemir and Tresiba being the leaders with the share of 50%, 25% and 9% of the market, respectively.&nbsp;</p>\n<p>With regard to Geropharm, according to the company&rsquo;s press-service, its portfolio includes seven insulin preparations of various action profiles, with five more are under development, including insulin glargine 300 U/ml, the duration of which is up to 36 hours.</p>\n<p>&nbsp;</p>", "date": "2021-03-02 10:05:00", "meta_title": "Russia\u00e2\u0080\u0099s Geropharm plots leading role in domestic insulin market", "meta_keywords": "Geropharm, Insulin degludec, Tresiba, Ryzodeg, Launches, Novo Nordisk, Rospatent, Biosimilars,", "meta_description": "Russia\u00e2\u0080\u0099s Geropharm plots leading role in domestic insulin market", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-03-02 09:48:28", "updated": "2021-03-02 10:05:12", "access": NaN, "url": "https://www.thepharmaletter.com/article/russia-s-geropharm-plots-leading-role-in-domestic-insulin-market", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "geropharm-big.jpg", "image2id": "geropharm-small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": "Insulin degludec", "sector_tag": "Biosimilars", "therapy area_tag": "Diabetes", "topic_tag": "Focus On, From our correspondent, In Depth, Patents & Trademarks, Russian market", "geography_tag": "Denmark, Russia", "company_tag": "Geropharm, Novo Nordisk", "drug_tag": "Degludec, Ryzodeg, Tresiba", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-03-02 10:05:00"}